A Phase 3, Open-label Study to Assess the Clinical Utility of Fluciclovine (18F) PET/CT in Patients With Prostate Cancer With Biochemical Recurrence After Radical Treatment

Trial Profile

A Phase 3, Open-label Study to Assess the Clinical Utility of Fluciclovine (18F) PET/CT in Patients With Prostate Cancer With Biochemical Recurrence After Radical Treatment

Suspended
Phase of Trial: Phase III

Latest Information Update: 26 Sep 2017

At a glance

  • Drugs Fluciclovine 18F (Primary)
  • Indications Prostate cancer
  • Focus Diagnostic use; Registrational
  • Acronyms FALCON
  • Sponsors Blue Earth Diagnostics
  • Most Recent Events

    • 26 Sep 2017 According to a Blue Earth Diagnostics media release, full results of this study will be available in a future peer reviewed publication.
    • 26 Sep 2017 Data from a pre-planned interim analysis of this trial published in a Blue Earth Diagnostics Media Release.
    • 26 Sep 2017 According to a Blue Earth Diagnostics media release, Status changed from active, no longer recruiting to suspended following successful results of a pre-planned interim analysis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top